geen (nu nog in gezonde mensen) not applicable
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age between 18-65 years - Good physical health evaluated by medical history, physical (including neurological) examination and screening laboratory tests - Weight >50 kg - RDC diagnosis never mentally ill - Written informed consent of each subject
Exclusion criteria
Exclusion criteria: - Any clinical significant abnormality of any clinical laboratory test - Any subject who has received any investigational medication within 30 days prior to the start of this study, or who is scheduled to receive an investigational drug - Major psychiatric or neurological disorder - History of alcohol and/or drug abuse (DSM-IV criteria) - History of coagulation problems - Any sign of cardiovascular disease - Current use of any medication, other than contraceptive medication - Breast feeding - Pregnancy - Unable to understand or read the Dutch language
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) To assess [11C]phenytoin plasma and brain kinetics in healthy volunteer(s), including assessment of the presence of radioactive metabolites in plasma. (2) To determine intra-subject variation of [11C]phenytoin kinetics in humans. | — |
Secondary
| Measure | Time frame |
|---|---|
| To develop a tracer kinetic model for [11C]phenytoin in humans. | — |
Countries
Netherlands